Intellia Therapeutics (NTLA) Misses Q4 EPS by 1c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results
February 27, 2020 7:30 AM ESTOn track to submit an IND application for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020 and to dose first patients in 2H 2020Plans to submit an IND application for NTLA-5001, a WT1-directed TCR-T cell therapy, for the treatment of acute myeloid leukemia in 1H 2021Expects to nominate a development candidate for the treatment of hereditary angioedema in 1H 2020Ends 2019 with a strong cash position of $284 million; cash runway through YE 2021
CAMBRIDGE, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:... More
